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Herbal medicines have been used in Japan for more than 1500 years and traditional
Japanese medicines (Kampo medicines) are now fully integrated into the modern
healthcare system. In total, 148 Kampo formulae are officially approved as prescription
drugs and covered by the national health insurance system in Japan. However, despite
their long track record of clinical use, the multi-targeted, multi-component properties
of Kampo medicines, which are fundamentally different from Western medicines,
have made it difficult to create a suitable framework for conducting well-designed,
large-scale clinical trials. In turn, this has led to misconceptions among western trained
physicians concerning the paucity of scientific evidence for the beneficial effects of
Kampo medicines. Fortunately, there has been a recent surge in scientifically robust
data from basic and clinical studies for some of the Kampo medicines, e.g., daikenchuto
(TU-100). Numerous basic and clinical studies on TU-100, including placebo-controlled
double-blind studies for various gastrointestinal disorders, and absorption, distribution,
metabolism and excretion (ADME) studies, have been conducted or are in the process
of being conducted in both Japan and the USA. Clinical studies suggest that TU-100
is beneficial for postoperative complications, especially ileus and abdominal bloating.
ADME and basic studies indicate that the effect of TU-100 is a composite of numerous
actions mediated by multiple compounds supplied via multiple routes. In addition to
known mechanisms of action via enteric/sensory nerve stimulation, novel mechanisms
via the TRPA1 channel and two pore domain potassium channels have recently been
elucidated. TU-100 compounds target these channels with and without absorption, both
before and after metabolic activation by enteric flora, with different timings and possibly
with synergism.
Keywords: Kampo, traditional Japanese herbal medicine, daikenchuto, adrenomedullin, hydroxy-α-sanshool,
transient receptor potential ankyrin 1, potassium leak channels
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Kampo: History and Comparison with
Western Drugs
Japanese traditional herbal medicine, called Kampo, is prescribed
for the treatment of a wide array of diseases and conditions,
including postoperative ileus, to alleviate the adverse effects
of anticancer therapies (such as neurotoxicity, oral mucositis,
and anorexia), and to manage the behavioral and psychological
symptoms of dementia (Kono et al., 2009; Matsuda et al., 2013;
Okada et al., 2015; Shimada et al., 2015). Because Kampo is
fully integrated into the modern healthcare system in Japan
(Motoo et al., 2011), it is neither a folk remedy nor an alternative
therapy. Kampo medicines are dispensed at all the university,
national, and foundation hospitals in Japan as prescription
drugs, frequently in combination with western drugs. Rooted
in Chinese medicine, knowledge of Kampo formulae have
been transmitted from generation to generation for 1500 years.
However, due to the problem of cultivating and procuring
identical species of some of the herbs in the Chinese formulae,
together with the limitedmaritime commerce at the time, Kampo
followed a decidedly unique path of development in the Japanese
archipelago. Consequently, there are stark differences between
Japanese and Chinese herbal formulae.
Until recently, it was much more difficult to ensure the
safety of traditional medicines made from natural sources by
comparison to modern drugs. However, this preconceived idea
has now been overturned by the establishment of a robust quality
control system for Kampo prescriptions, which ensures that
the cultivation and harvest of botanical raw materials are in
accord with World Health Organization Good Agricultural and
Collection Practices guidelines for medicinal plants. Moreover,
Kampo medicines are now manufactured in accord with both
Japanese good manufacturing practice (GMP) and Kampo
GMP guidelines, the former provided by law and the latter
by self-imposed standards introduced by an association of
industrial bodies. In addition, at least for the top selling
Kampo products, which comprise over 80% of the market
share, extensive component analysis and quality inspection for
residual agrichemicals, heavy metals, aflatoxin, microorganisms,
and other contaminants at critical steps in the manufacturing
process guarantee the manufacture of safe, high-quality, and
standardized Kampo products. Since 1967 when the Japanese
government initially approved four prescriptions, the number
of approved Kampo prescriptions has been steadily increasing,
and at present 148 Kampo prescriptions (Japan Pharmaceutical
Information Center Kampo extract granules for ethical use
2014) are covered by the national health insurance system and
are officially registered by the Japanese Ministry of Health as
multicomponent remedies containing extracts derived mainly
from plant-based and mineral-based substances. As prescription
drugs, Kampo is considered to be in the same class as western
Abbreviations: GMP, good manufacturing practice; TU-100, daikenchuto; CGRP,
calcitonin gene-related peptide; HAS, hydroxy-α-sanshool; HBS, hydroxy-β-
sanshool; ADM, adrenomedullin; IECs, intestinal epithelial cells; TRPV1, transient
receptor potential vanilloid receptor 1; TRPA1, transient receptor potential
ankyrin 1; KCNK, potassium leak channels, two-pore-domain subfamily K.
drugs. In recent years, the Food and Drug Administration has
displayed a keen interest in Kampo, such that daikenchuto (TU-
100), the most widely used Kampo in Japan, has been approved as
an investigational new drug andmultiple clinical trials examining
its safety and efficacy are currently underway (www.clinical
trails.gov). The first trial conducted at the Mayo Clinic showed
that TU-100 significantly accelerated colonic motility in healthy
volunteers in direct comparison to placebo (Manabe et al.,
2010). Furthermore, investigators at the Universities of Chicago,
California, and Oxford have undertaken studies to clarify the
pharmacological mechanisms of Kampo in line with their
emerging interest in multicomponent remedies (Ueno et al.,
2014; Wang et al., 2014).
Nonetheless, there are western-trained physicians in every
country who continue to deprecate herbal medicines, owing to
a fundamental lack of understanding concerning the differences
between Kampo and western drugs (Kono et al., 2009). As
described in Table 1, the ideal drug in western medicine is a
magic bullet with a single target, which in reality frequently
acts on unintended targets producing unwanted side effects.
By contrast, Kampo contains multiple components that act
synergistically and cooperatively on multiple targets, resulting in
a substantially lowered risk of developing side effects (Terasawa,
2004a). Another major difference is that a candidate, novel
compound in western medicine can take anywhere from 10
to 15 years to verify its efficacy in pharmacokinetic and basic
studies as well as placebo-controlled clinical trials before it is
approved as a pharmaceutical drug for the market. By contrast,
Kampo has been clinically used in humans and its content refined
empirically for approximately 1500 years (Terasawa, 2004b).
Given that rigorous scientific investigations of Kampo have only
commenced in the last few decades, allopathic physicians have
necessarily been skeptical about their use. Fortunately, however,
several Kampo products, including daikenchuto, are currently
subjected to stringent scientific analyses commensurate with
those employed for conventional new drug development.
Daikenchuto
Daikenchuto has been officially registered since 1986 and is the
most widely prescribed Kampo in Japan with the greatest amount
of preclinical and clinical evidence (Kono et al., 2009). The
traditional herbal medicine daikenchuto is an extract containing
three medicinal herbs, which are also well-known culinary
herbs. The three herbs are Japanese pepper (Zanthoxylum fruit),
processed ginger (Zingiberis Siccatum Rhizoma), and ginseng
(Ginseng radix). The traditional medicine is made by mixing
the herbs in defined ratios, followed by extraction using hot
water, and finally the extract is made into a powder (Figure 1).
Daikenchuto is primarily administered for the treatment of
two symptoms: abdominal bloating and cold sensation in the
abdomen. The effect of daikenchuto in alleviating abdominal
bloating accompanying postoperative ileus appears to correlate
with its effect on improving colonic motility as confirmed
in several placebo-controlled, double-blind trials (Kono et al.,
2009; Manabe et al., 2010; Iturrino et al., 2013; Okada et al.,
2013; Shimada et al., 2015). TU-100 is also known as one of
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TABLE 1 | Differences between Western and Kampo medicines.
Ideal
Western (Allopathic) medicines Single compound Single target (Magic bullet) High selectivity No side effect
Reality
Unintended multiple targets Efficacious but with serious side effects
Kampo medicines Compatible compound groups Intended multiple targets Efficacious with few side effects
FIGURE 1 | Daikenchuto components and its manufacturing process. Daikenchuto is a herbal formulation consisting of processed ginger, Japanese pepper,
and ginseng radix. The normal adult dosage is between 7.5 and 15 g given as two or three doses.
the representative prescriptions for the treatment of chronic
constipation (Iizuka and Hamamoto, 2015).
Meanwhile, mechanistic studies are increasingly
demonstrating that the prokinetic effect of daikenchuto could be
ascribed to its effect on neurotransmitters such as acetylcholine
and calcitonin gene-related peptide (CGRP) (Nagano et al.,
1999; Shibata et al., 1999; Jin et al., 2001). However, until
recently, compound analysis and pharmacokinetic studies,
which are considered indispensable in conventional drug
development, have been sparse because of difficulties in
simultaneously tracking multiple components in the Kampo
medicine. Nonetheless, the advent of technologies such as liquid
chromatography-mass spectrometry for the identification of
compounds and characterization of their kinetics with greater
accuracy and precision (Munekage et al., 2011, 2013) has
facilitated the analysis of daikenchuto. The use of 3D-HPLC
has helped identify the multiple compounds in Kampo, but the
pharmacokinetic data has revealed for the first time that these
compounds are absorbed and metabolized at different rates.
For instance, our data showed that the main active compounds
of Japanese pepper, namely, hydroxy-α-sanshool (HAS) and
hydroxy-β-sanshool (HBS), produce transient peaks, indicating
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their rapid absorption at high concentrations (HAS in the
order of µM) as well as their rapid elimination over a period
of a few hours (Munekage et al., 2011, 2013). The main active
compounds of processed ginger ([6]-shogaol and [6]-gingerol)
are also absorbed, but then rapidly metabolized and conjugated
after absorption. Consequently, the plasma concentrations of
[6]-shogaol and [6]-gingerol are <1% compared with that of
the Japanese pepper compounds (Watanabe et al., in press). By
contrast, most of the ginseng compounds remain unabsorbed.
Moreover, pharmacokinetic analysis of luminal content after
FIGURE 2 | Diagrammatic representation of the hypothesized journey
of TU-100 compounds after ingestion. The concentrations of TU-100
compounds and their conjugates after oral administration of TU-100 in rat
intestinal, portal blood and peripheral blood and in human ileal effluent and
peripheral blood were measured in several PK studies (Munekage et al., 2011,
2013; Watanabe et al., in press). The results are summarized as indicated in
the figure. The diagram of digestive sysytem (A), and the fate of Japanese
pepper (B), Ginger (C) and ginseng (D) ingredients are shown. The effect of
TU-100 on the intestines should be a composite of multiple actions by multiple
compounds supplied via multiple routes. Quoted from Watanabe et al. (in
press).
administration revealed that Japanese pepper compounds are
rapidly absorbed before reaching the colonic lumen (Watanabe
et al., in press). Processed ginger compounds are transformed
into various metabolites in the upper small intestine and liver
with some compounds entering the enterohepatic circulation
(Watanabe et al., in press). Ginseng compounds reach the
colon intact and are absorbed only after they are metabolized
by the enteric microbiota (Watanabe et al., in press). Among
the bacterial metabolites of ginseng compounds, some have
been found to have antitumor and anti-inflammatory properties
such as compound K (20-O-(β-D-glucopyranosyl)-20(S)-
protopanaxadiol) (Wakabayashi et al., 1997; Bae et al., 2002;
Tachikawa and Kudo, 2004). Taken together, one of the key
findings from the pharmacokinetic study is that the compounds
are absorbed at different rates and act accordingly on various
target cells (Figure 2). The significance of this finding will be
elaborated after the explanation of one of the other important
pharmacological effects of daikenchuto.
As mentioned earlier, daikenchuto is primarily prescribed
for the treatment of abdominal bloating and cold sensation
in the abdomen. The clinical improvement in relieving cold
sensation in the abdomen after administration of daikenchuto
has previously been attributed to its effect in improving intestinal
blood flow (Takayama et al., 2010). We have found that the
critical players responsible for these effects are the two peptides,
CGRP and adrenomedullin (ADM) (Kono et al., 2008, 2009,
2010, 2011, 2013; Kaneko et al., 2013). Although the two
peptides have strikingly similar vasodilatory, anti-inflammatory,
and antibacterial properties, they are produced by different
FIGURE 3 | Multi-target actions of intraluminal TRPA1 agonists. Gut
TRPA1 elicits physiological and pathophysiological responses by three distinct
mechanisms. TRPA1 activators, in this case shogaols, gingerols and
hydroxysanhools, have three potential target cells: intestinal epithelial (IE) cells,
enterochromaffin (EC) cells, and TRPA1-positive sensory neurons. As a result
of TRPA1 stimulation, TRPA1 agonists stimulate IE cells to release ADM, EC
cells to release 5-HT, and sensory neurons to release CGRP/substance P,
respectively, resulting in physiological and biodefensive responses in
vasodilatation, motility, secretion, and pain signaling. Quoted from Kono et al.
(2013).
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tissues, i.e., CGRP by neuronal tissues and ADM by a wide
range of various tissues other than neuronal cells, especially by
endothelial and vascular smooth muscle cells in heart, lung,
kidney, and cerebral vasculature (Brain and Grant, 2004). The
intestinal epithelial cells (IECs) are particularly endowed with the
ability to produce ADM because we have found that daikenchuto
administered into the intestinal lumen causes an immediate
increase in blood flow in both the small and large intestines
(Kono et al., 2011, 2013). When this data is presented at
academic meetings in the West, one of the frequently asked
questions is whether the effect of daikenchuto is equivalent to
that induced by capsaicin. We have discovered that this is not
the case because the daikenchuto-induced increase in blood flow
is not abrogated by the inhibitors of transient receptor potential
vanilloid receptor 1 (TRPV1), a capsaicin receptor. Another
common point of contention is whether an augmentation of
blood flow will aggravate pre-existing inflammation. Our results
from the experimental colitis model have shown that blood flow
increases in areas of poor circulation, while it remains unchanged
in regions of high levels of inflammation (Kono et al., 2011).
This is most likely due to the mobilization and exhaustion of
the two primary targets of daikenchuto, i.e., CGRP and ADM,
in inflamed areas and that the Kampo remedy itself is neither
CGRP nor ADM. In addition, mechanistic probing of ADM
production has revealed that daikenchuto induces ADM release
from the IECs in a dose- and time-dependent manner largely
via its active compound, [6]-shogaol. Furthermore, [6]-shogaol
appears to stimulate a type of Ca2+channel called the transient
receptor potential ankyrin 1 (TRPA1), to promote ADM release
from the IECs as well (Kono et al., 2013). It should be noted
that TRPA1 is expressed in enterochromaffin cells and sensory
neurons as well as in IEC. HAS, [6]-gingerol and [6]-shogaol
are all known to have TRPA1-stimulating activity (Riera et al.,
2009). Because the compounds are transported to various target
cells via different routes as described in the previous paragraph,
TU-100 could stimulate TRPA1 in all these cell types (Figure 3).
CGRP-mediated effects on intestinal blood flow (Murata et al.,
2002) and substance P-mediated contraction of intestinal smooth
muscle (Satoh et al., 2001) by TU-100 is thought to occur via
sensory nerves. The possible involvement of TRPA1-induced
serotonin release from enterochromaffin cells in the TU-100-
mediated prokinetic effect is currently being investigated in our
laboratory.
However, pharmacokinetic data has shown that the plasma
concentration of [6]-shogaol is low and does not correspond
with the effective dose observed in in vitro studies, but such
a dose would likely be considered high in the lumen. It has
been confirmed that daikenchuto administered directly using
a long tube is clinically effective in patients (Yasunaga et al.,
2011). In subsequent studies, we analyzed the kinetics of Japanese
pepper compounds, HAS and HBS, which are known agonists
of TRPA1 and TRPV1 receptors (actions resembling those of
processed ginger compounds) and antagonists of potassium leak
channels, two-pore-domain subfamily K (KCNK) (Kubota et al.,
2015). KCNK channels exist in cell membranes of excitatory cells
such as neurons and muscles as highly regulated, K+-selective
leak channels (Mackinnon et al., 1998; Bautista et al., 2008).
As such, these channels are fundamental to maintaining the
resting potential of the cell and regulating cellular excitability.
In the neurons, KCNK channels regulate the opening of voltage-
gated Na+ channels, which generate action potentials. Recent
studies have shown that HAS and HBS accelerate colonic motility
FIGURE 4 | Hypotheses on synergism of TU-100 compounds on
colonic motility. (A) Two-pore-domain potassium channels (i.e., KCNKs
family channels) are expressed in many types of excitable cells throughout
the body and have been implicated in various cellular functions, including the
maintenance of the resting potential and regulation of excitability. Low doses
of ginger compounds cannot evoke action potentials. (B) One of compounds
of daikenchuto, hydroxy-α-sanshool, acts as a blocker of two-pore-domain
potassium leak channels (KCNK3 and KCNK9) and alters the excitability of a
cell via voltage-activated cation channels. Low doses of ginger compounds
can evoke action potentials.
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by inhibiting KCNK3 and KCNK9 channels in the intestinal
smooth muscle and neuronal cells (Kubota et al., 2015). In
light of these findings, combined with the pharmacokinetic data,
we postulated the hypothesis outline in Figure 4. Daikenchuto
administration causes an initial blockade of KCNK channels in
the intestinal smooth muscle and neuronal cells by the action
of the Japanese pepper compounds, which leads to increased
membrane sensitivity. Thus, there is a decreased threshold for
additional exogenous stimuli, such as subsequent exposure to
ginger and ginseng compounds. In short, these results suggest
that daikenchuto compounds could induce a therapeutic effect
at concentrations lower than those required for each compound
to exert its effect alone. Indeed, preliminary investigations, using
experimental systems described above, suggest that Japanese
pepper and processed ginger, and Japanese pepper and ginseng,
exhibit synergistic effects on intestinal blood flow and colonic
motility, respectively (unpublished data). Unraveling the precise
mechanisms underpinning these synergistic effects will be an
enormous task. Nevertheless, taking into consideration all the
available data, our hypothesis appears to be both robust and
credible. We believe that systems biology will be particularly
useful for elucidating multicomponent remedies and has the
potential of producing groundbreaking results that could
instigate a paradigm shift in healthcare.
Contemporary Kampo is a classic example of the
harmonization between traditional herbal medicine and
modern medicine. Rigorous scientific investigations are now
beginning to reveal the complex therapeutic effects mediated
by Kampo. The ancient adage of maximizing the temporal
differences in pharmacological effects may be similar to the
modern concept of a combination chemotherapy regimen,
except that one Kampo prescription by itself fulfills the role
of a combination regimen. We conjecture that Kampo is
likely to benefit many patients, particularly those whose
condition remains recalcitrant to conventional treatments.
As such, we advocate the worldwide availability of Kampo
medicines.
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